Can I Take Ginseng with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Does the Supplement Question Matter?

Resmetirom (Rezdiffra) received FDA approval in March 2024, making it the first drug specifically approved for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis. Patients with MASH frequently use herbal supplements, often without telling their hepatologist, which creates real clinical exposure.

Resmetirom's Mechanism in Brief

Resmetirom acts as a selective thyroid hormone receptor beta (THR-beta) agonist. THR-beta predominates in the liver, so the drug reduces hepatic fat, lowers LDL cholesterol, and modulates glucose metabolism without the cardiac side effects that would come from activating thyroid receptors elsewhere. The phase 3 MAESTRO-NASH trial (N=966) showed resmetirom 100 mg produced MASH resolution in 25.9% of patients versus 14.2% on placebo at 52 weeks [1].

Because the drug directly touches hepatic lipid and glucose metabolism, any supplement that also modifies glucose or lipid handling enters a zone of potential overlap.

Who Takes Both?

Patients with MASH often have type 2 diabetes, obesity, or metabolic syndrome. Ginseng is one of the top-selling herbal supplements in the United States, with annual retail sales exceeding $300 million, and it is marketed heavily for energy, blood sugar support, and immune function. The intersection is not theoretical. A 2017 NHANES analysis found that roughly 34% of adults with liver disease used at least one herbal supplement [2].

Understanding Ginseng: Species, Constituents, and Biological Activity

"Ginseng" is not a single compound. The term covers at least two botanically distinct species with different ginsenoside profiles and different clinical effects.

Panax Ginseng vs. Panax Quinquefolius

Panax ginseng (Asian or Korean ginseng) contains primarily Rb1, Rb2, Rc, Rd, Re, and Rg1 ginsenosides. Panax quinquefolius (American ginseng) is higher in Rb1 and lower in Rg1. Ginsenoside Rb1 has shown insulin-sensitizing effects in animal hepatocyte models [3]. Rg1 has demonstrated anti-inflammatory signaling in rodent NASH models, though human trial data remain sparse.

Glucose-Lowering Activity

A Cochrane-adjacent systematic review of 16 randomized controlled trials (N=770) found that Panax ginseng and Panax quinquefolius reduced fasting blood glucose by a mean of 0.31 mmol/L (about 5.6 mg/dL) versus placebo, a modest but measurable shift [4]. In patients whose glucose metabolism is already being altered by resmetirom's THR-beta activity, this additive lowering could push susceptible individuals toward hypoglycemia, particularly if they are also on metformin or a sulfonylurea.

Anticoagulant and Platelet Effects

Several ginsenosides inhibit platelet aggregation through thromboxane B2 suppression and ADP pathway modulation. A 2003 study in healthy volunteers found that standardized American ginseng extract reduced platelet aggregation by approximately 12% after four weeks at 1,000 mg daily [5]. For MASH patients who already have portal hypertension, varices, or thrombocytopenia from hypersplenism, even modest antiplatelet effects deserve attention.

The Pharmacokinetic Question: Does Ginseng Affect Resmetirom Blood Levels?

This is the part most patients ask first, and the answer requires nuance.

Resmetirom's Metabolic Pathway

The prescribing information for Rezdiffra identifies resmetirom as a substrate of CYP2C8 and an inhibitor of OATP1B1 and OATP1B3 hepatic uptake transporters [6]. Strong CYP2C8 inhibitors (like gemfibrozil) can meaningfully increase resmetirom exposure and are flagged in the label.

Where Ginseng Fits

Ginseng has been studied for CYP enzyme effects with inconsistent results. A 2004 pharmacokinetic study found that Panax ginseng did not significantly alter midazolam (CYP3A4) or debrisoquine (CYP2D6) pharmacokinetics in healthy adults [7]. Data specifically examining ginseng's effect on CYP2C8 substrates in humans are limited.

One in vitro study showed ginsenoside Rb1 inhibited CYP2C8-mediated amodiaquine hydroxylation at a concentration of 50 micromolar [8]. Whether those concentrations are achievable at typical oral ginseng doses (200-400 mg standardized extract daily) in human plasma is uncertain. Oral bioavailability of intact ginsenosides is low because gut bacteria transform them into secondary metabolites, and plasma Rb1 levels from standard doses are likely well below 50 micromolar.

The current evidence does not confirm a clinically significant pharmacokinetic interaction between ginseng and resmetirom. That absence of evidence is not evidence of absence, especially given the lack of dedicated human pharmacokinetic trials.

A Clinical Risk-Stratification Framework for Ginseng Use in Resmetirom Patients

Based on the available evidence, clinicians at HealthRX use the following three-tier approach when a patient on resmetirom asks about ginseng:

Tier 1: Low-concern profile. Patient has F2 fibrosis, no diabetes, no anticoagulant use, normal platelet count above 150,000/mcL, and wants a standardized Panax ginseng extract at 200 mg daily. Discussion and disclosure are sufficient; no formal dose adjustment needed. Monitor fasting glucose at next scheduled visit.

Tier 2: Moderate-concern profile. Patient has F3 fibrosis, pre-diabetes or type 2 diabetes managed with metformin or a GLP-1 agonist, and plans to use ginseng at 400-600 mg daily. Baseline fasting glucose and HbA1c before starting; recheck at four weeks. Counsel on hypoglycemia signs.

Tier 3: Higher-concern profile. Patient has advanced fibrosis, thrombocytopenia (platelets <100,000/mcL), portal hypertension, or concurrent warfarin or antiplatelet therapy. Defer ginseng or substitute a product without known platelet effects (e.g., a non-ginsenoside herbal for fatigue) until formal pharmacist review is complete.

Pharmacodynamic Interactions: The More Immediate Clinical Concern

Pharmacodynamic interactions occur when two agents produce overlapping physiological effects, regardless of whether they share a metabolic pathway. For ginseng and resmetirom, two pharmacodynamic concerns stand out.

Glucose Overlap

Resmetirom's THR-beta activation increases hepatic glucose uptake and modulates gluconeogenesis. Its phase 3 data showed a statistically significant reduction in HOMA-IR (a measure of insulin resistance) at 52 weeks compared to placebo [1]. Ginseng independently lowers fasting glucose, as noted above. Together, the reduction could be additive rather than synergistic in the mathematical sense, but still clinically meaningful for a patient on a sulfonylurea or insulin.

The American Diabetes Association's 2024 Standards of Care note that herbal supplements with glucose-lowering activity should be disclosed to providers and are not recommended as replacements for approved therapies, partly because their potency is variable across product batches [9].

Anticoagulant Overlap

Patients with MASH and advanced fibrosis may already have impaired clotting factor synthesis. Adding ginseng's mild antiplatelet effects could extend bleeding time in a patient who is already coagulopathic. If the patient is concurrently on warfarin for atrial fibrillation (a common comorbidity in the MASH population), one case series documented a 0.5-1.0 point INR reduction with high-dose Panax ginseng, suggesting ginseng may paradoxically reduce warfarin effect rather than potentiate it through an unclear mechanism [10]. This bidirectional uncertainty is precisely why disclosure matters.

What Resmetirom's FDA Label Says About Drug Interactions

The Rezdiffra prescribing information (approved March 2024) warns against concurrent use of strong CYP2C8 inhibitors and recommends avoiding co-administration with drugs that are OATP1B1/1B3 substrates at higher resmetirom doses [6]. Herbal supplements are not individually listed, as is standard for FDA labeling, but the underlying metabolic pathway information applies.

The FDA label also recommends monitoring liver enzymes, because resmetirom is itself hepatically cleared and its target organ is the liver. Adding any supplement with potential hepatotoxicity would compound this risk. Ginseng at typical doses has a low hepatotoxicity signal in the published literature, but adulterated ginseng products (a documented problem in dietary supplement quality) have caused liver injury in case reports [11].

Third-Party Testing Matters Here

If a patient chooses to continue ginseng, they should select a product certified by NSF International, USP, or ConsumerLab to reduce the risk of contamination or mislabeling. An adulterated product spiked with phenolphthalein or other compounds could introduce entirely different interaction risks.

Monitoring Plan When Combining Ginseng and Resmetirom

Patients who disclose ginseng use to their clinician and are assessed as Tier 1 or Tier 2 risk (per the framework above) should follow this schedule:

Baseline Labs Before Starting Ginseng

• Fasting glucose and HbA1c
• CBC with platelet count
• INR or PT if on anticoagulant therapy
• AST, ALT, and total bilirubin (already recommended by the Rezdiffra label)

Follow-Up Schedule

Recheck fasting glucose at four weeks after starting ginseng. If HbA1c was borderline at baseline, recheck at three months. Platelet count and INR (if applicable) should be reviewed at the next scheduled hepatology visit, typically at 12 weeks on resmetirom.

Stopping Rules

Discontinue ginseng and notify your prescriber if you experience:

• Blood glucose readings below 70 mg/dL without a clear dietary explanation
• Unusual bruising or prolonged bleeding from minor cuts
• New fatigue, jaundice, or right upper quadrant discomfort (possible hepatotoxicity signal)
• Any INR change greater than 0.5 points from your stable baseline

Ginseng and Liver Health: Does It Help or Hurt in MASH?

This question is medically interesting because some ginsenosides have shown anti-fibrotic and anti-inflammatory effects in animal NASH models.

Preclinical Data

Ginsenoside Rg1 reduced hepatic steatosis scores and lowered serum ALT in a high-fat-diet mouse model, likely through AMPK activation and PPAR-alpha upregulation [12]. Ginsenoside Rb1 reduced TGF-beta1-mediated stellate cell activation in vitro, suggesting a potential anti-fibrotic signal.

The Human Evidence Gap

No phase 2 or phase 3 randomized controlled trial has tested ginseng against MASH endpoints in humans. The preclinical data are mechanistically interesting but not clinically actionable. Resmetirom's MAESTRO-NASH data [1] represent a 966-patient, randomized, double-blind, placebo-controlled trial with histological endpoints. Ginseng has no comparable dataset. Patients should not substitute ginseng for resmetirom or view it as an adjunct proven to enhance resmetirom's efficacy.

Product Quality in the Supplement Industry

A 2023 ConsumerLab review of 30 commercially available ginseng products found that 7 (23%) failed to meet label claims for ginsenoside content, and 3 contained detectable pesticide residues. This variability means the "dose" of active compound a patient receives could range from near-zero to several times the labeled amount across different bottles or brands.

Practical Advice if You Are Already Taking Both

Some patients arrive at a consultation already combining ginseng and resmetirom, often because they started ginseng before their MASH diagnosis and Rezdiffra prescription.

Do Not Stop Resmetirom Without Medical Guidance

Resmetirom addresses liver fibrosis progression, a serious clinical outcome. Stopping it without a clinical conversation is not appropriate based on supplement concern alone.

Disclose at Your Next Visit

Bring the ginseng product's label (including brand name, dose per serving, and ginsenoside standardization percentage) to your next hepatology or telehealth appointment. The clinician can assess your specific risk tier and decide whether monitoring adjustment is needed.

Consider Switching to a Lower-Risk Product

If ginseng is being used primarily for fatigue, a clinician may suggest alternative strategies, such as addressing sleep quality, optimizing thyroid function (relevant given resmetirom's thyroid receptor mechanism), or reviewing whether other medications are contributing to fatigue.